Profile data is unavailable for this security.
About the company
Transgene SA is a biopharmaceutical company. The Company designs and develops immunotherapy products to treat cancer and infectious diseases. These products use viral vectors to directly or indirectly destroy diseased cells. The Company has approximately three products in clinical development: two immunotherapy products for cancer treatment and an anti-infective immunotherapy product for chronic hepatitis B. The Company also has various other programs based on its viral vector technology in research or in pre-clinical or clinical development. The Company's activities are focused on human health and, in particular, the research and development of immunotherapy products, including therapeutic vaccines and oncolytic viruses in the field of cancer and infectious diseases. The Company's principal products include TG4010 (MVA-MUC1-IL2), Pexa-Vec (VV-TK-GM-CSF), TG6002 (VV-TK-RR-FCU1), TG1050 (Ad5-HBV) and TG4001 (MVA-HPV-IL2).
- Revenue in EUR (TTM)7.63m
- Net income in EUR-22.33m
- Incorporated1979
- Employees158.00
- LocationTransgene SA400 Boulevard Gonthier d'AndernachParc d'Innovation - CS80166ILLKIRCH-GRAFFENSTADEN 67405FranceFRA
- Phone+33 388279100
- Fax+33 388279111
- Websitehttps://www.transgene.fr
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AFYREN SA | 3.38m | -9.59m | 70.52m | 122.00 | -- | 1.14 | -- | 20.87 | -0.3696 | -0.3696 | 0.1303 | 2.37 | 0.0435 | -- | 5.39 | 27,696.72 | -12.35 | -9.58 | -13.42 | -10.46 | 92.63 | 95.57 | -283.69 | -162.61 | -- | -1.62 | 0.0719 | -- | -2.23 | -- | -4.20 | -- | -- | -- |
| Maat Pharma SA | 2.23m | -19.72m | 91.77m | 50.00 | -- | 4.48 | -- | 41.19 | -1.73 | -1.73 | 0.196 | 1.76 | 0.0508 | 4.84 | 4.16 | 44,560.00 | -44.99 | -35.49 | -58.93 | -42.98 | 74.28 | -- | -884.96 | -1,157.54 | 2.76 | -49.61 | 0.4075 | -- | 55.80 | -- | -43.78 | -- | 30.30 | -- |
| Eurofins-Cerep SA | 46.17m | 9.21m | 109.96m | 233.00 | 11.94 | 1.83 | 9.82 | 2.38 | 1,826.41 | 1,826.41 | 9,160.00 | 11,939.29 | 0.6814 | 1.66 | 6.04 | 220,892.00 | 13.60 | 15.19 | 16.06 | 18.94 | 85.57 | 67.30 | 19.95 | 19.72 | 5.17 | 112.42 | 0.00005 | 0.00 | 14.45 | 14.30 | 17.09 | 24.52 | -- | -- |
| AB Science SA | 777.00k | -16.89m | 115.08m | 89.00 | -- | -- | -- | 148.10 | -0.3561 | -0.3561 | 0.0164 | -0.3879 | 0.0284 | 0.394 | 2.50 | 7,471.15 | -61.64 | -70.81 | -237.22 | -316.63 | 88.16 | 91.37 | -2,173.10 | -1,225.49 | 1.41 | -- | 135.44 | -- | -40.39 | -11.24 | 5.86 | -- | 5.07 | -- |
| DBV Technologies SA | 4.83m | -93.29m | 125.95m | 88.00 | -- | 0.83 | -- | 26.06 | -0.9901 | -0.9901 | 0.0513 | 1.57 | 0.0209 | -- | 0.3738 | 70,056.35 | -40.35 | -64.67 | -46.22 | -80.94 | -- | 91.59 | -1,929.97 | -1,345.10 | -- | -- | 0.0128 | -- | -15.14 | -18.45 | 2.08 | -- | -38.41 | -- |
| Transgene SA | 7.63m | -22.33m | 133.93m | 158.00 | -- | 8.55 | -- | 17.54 | -0.2227 | -0.2227 | 0.0759 | 0.1553 | 0.1368 | -- | 4.28 | 48,316.46 | -40.00 | -24.81 | -50.27 | -29.79 | -- | -- | -292.48 | -193.24 | -- | -- | 0.4764 | -- | -23.68 | 1.51 | 31.94 | -- | 14.44 | -- |
| Adocia SA | 2.15m | -21.16m | 138.23m | 78.00 | -- | -- | -- | 64.29 | -1.93 | -1.93 | 0.194 | -0.4908 | 0.0774 | 2.62 | 7.44 | 27,564.10 | -76.16 | -43.08 | -396.14 | -72.93 | 7.91 | -- | -984.28 | -514.53 | 1.01 | -2.07 | 2.12 | -- | -81.22 | -46.13 | -206.65 | -- | -27.60 | -- |
| Eurobio Scientific SA | 130.00m | 4.84m | 151.27m | 137.00 | 34.21 | 0.9212 | 6.50 | 1.16 | 0.4315 | 0.4315 | 11.59 | 16.02 | 0.4018 | 3.19 | 4.31 | 948,927.00 | 1.49 | 16.91 | 1.80 | 21.53 | 47.11 | 50.95 | 3.72 | 23.34 | 2.32 | 2.81 | 0.3666 | 0.00 | -14.81 | 20.80 | -80.61 | -- | 20.02 | -- |
| Ose Immunotherapeutics SA | 2.23m | -23.00m | 164.13m | 62.00 | -- | 7.08 | -- | 73.70 | -1.18 | -1.18 | 0.1166 | 1.06 | 0.0256 | -- | 3.22 | -- | -26.46 | -17.17 | -33.15 | -20.55 | -- | -- | -1,032.87 | -94.71 | -- | -97.81 | 0.6659 | -- | -87.83 | -38.07 | -29.52 | -- | -17.11 | -- |
| Genfit SA | 38.18m | -28.89m | 172.68m | 159.00 | -- | 2.54 | -- | 4.52 | -0.5814 | -0.5814 | 0.7681 | 1.36 | 0.1961 | 542.00 | 3.52 | 240,100.60 | -14.84 | -12.57 | -18.55 | -15.30 | 94.32 | 94.96 | -75.69 | -76.23 | 2.94 | -7.78 | 0.5080 | -- | 43.70 | 38.49 | -21.82 | -- | -3.27 | -- |
| Aelis Farma SA | 9.05m | -5.08m | 173.68m | 26.00 | -- | 13.16 | -- | 19.18 | -0.3907 | -0.3907 | 0.7019 | 0.9957 | 0.2765 | -- | 2.41 | 348,230.80 | -15.51 | -24.53 | -25.59 | -40.55 | -- | -- | -56.09 | -109.62 | 2.47 | -- | 0.1547 | -- | 137.70 | -- | 64.46 | -- | 37.35 | -- |
| Inventiva SA | 17.48m | -110.43m | 178.95m | 112.00 | -- | -- | -- | 10.24 | -2.45 | -2.45 | 0.3854 | -0.6146 | 0.1884 | -- | 9.18 | 156,044.60 | -116.84 | -54.30 | -207.08 | -69.98 | -- | -- | -620.31 | -669.97 | 0.9524 | -19.98 | 6.96 | -- | 43.50 | 40.46 | -103.46 | -- | -0.33 | -- |
| Innate Pharma SA | 51.90m | -7.57m | 189.21m | 179.00 | -- | 3.64 | -- | 3.65 | -0.0939 | -0.0939 | 0.6451 | 0.642 | 0.2648 | -- | 5.67 | 289,949.70 | -3.86 | -8.83 | -4.87 | -12.11 | 94.50 | 93.17 | -14.59 | -55.55 | -- | -- | 0.6408 | -- | 4.68 | -8.27 | 86.94 | -- | 10.50 | -- |
| Cellectis SA | 8.46m | -100.74m | 196.19m | 235.00 | -- | 2.52 | -- | 23.19 | -1.73 | -1.62 | 0.1531 | 1.09 | 0.0309 | -- | 13.71 | 36,004.88 | -39.24 | -24.08 | -60.81 | -30.69 | -- | -64.64 | -1,270.92 | -308.24 | -- | -5.08 | 0.5429 | -- | -64.26 | -15.57 | -20.55 | -- | -26.15 | -- |
Data as of May 17 2024. Currency figures normalised to Transgene SA's reporting currency: Euro EUR
1.55%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BFT Investment Managers SAas of 28 Mar 2024 | 862.91k | 0.86% |
| Tocqueville Finance SAas of 31 Jan 2024 | 244.10k | 0.24% |
| Soci�t� G�n�rale Gestion SAas of 28 Mar 2024 | 195.94k | 0.19% |
| Erasmus Gestion SASas of 30 Apr 2024 | 174.74k | 0.17% |
| Financi�re Arbevel SAas of 30 Dec 2022 | 87.00k | 0.09% |
More ▼
Data from 31 Dec 2023 - 30 Apr 2024Source: FactSet Research Systems Inc.
